JAK2 and myeloproliferative neoplasm: Furthermore, combining JAK2 and PI3K inhibitors inhibited Epo-independent CFU-E and BFU-E colony formation from primary cells from JAK2 V617F-positive MPN patients and JAK2 V617F knock-in mice.